Diagnostic Dilemma of Biliopancreatic Contrast-Enhanced Harmonic Endoscopic Ultrasonography

• Published in: Diagnostics (Basel) Vol. 12; no. 8; p. 1983
• Main Authors: Kanazawa, Keisuke, Chiba, Masafumi, Kato, Masayuki, Kinoshita, Yuji, Akasu, Takafumi, Matsui, Hiroaki, Shimamoto, Nana, Tomita, Youichi, Abe, Takahiro, Tsukinaga, Shintaro, Nakano, Masanori, Torisu, Yuichi, Toyoizumi, Hirobumi, Sumiyama, Kazuki
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.08.2022; MDPI
• Subjects: Analysis; biliary tract diseases; Biopsy, Needle; Care and treatment; Clinical medicine; Cysts; Diagnosis; diagnostic performance; Disease; Endoscopic ultrasonography; Endoscopy; endosonography; Gallbladder; Hospitals; Magnetic resonance imaging; Pancreatic cancer; Pancreatic diseases; Pathology; Risk factors; Ultrasonic imaging; ultrasound contrast agents; Values; Japan; biliary tract diseases; diagnostic performance; pancreatic diseases; ultrasound contrast agents; endosonography
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics12081983

Background: The utility of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) alone in the biliopancreatic region appears to be limited because it is highly dependent on the experience and skill of the endoscopist. Therefore, the present study aimed to validate the efficacy of CH-EUS in clinical practice. Methods: Between January 2018 and March 2019, 301 consecutive patients who underwent CH-EUS were prospectively enrolled in this study. The diagnostic performance of CH-EUS was compared with that of dynamic computed tomography (CT), magnetic resonance imaging (MRI), and all combinations (i.e., CH-EUS, dynamic CT, and MRI) using a Bonferroni correction. A multiple logistic regression analysis was performed to extract each disease that allowed the CH-EUS diagnosis to be consistent with the final diagnosis. Results: In multiple comparisons of diagnostic performance, no significant differences were observed among dynamic CT, MRI, and CH-EUS (p = 1.00), but the diagnostic performance was significantly higher when all modalities were combined (p < 0.001). Moreover, only intraductal papillary mucinous neoplasm comprising adenoma or carcinoma (IPMN, n = 161) showed significance with respect to the agreement with the final diagnosis (p = 0.006). Conclusions: Our results showed that CH-EUS-based diagnosis of IPMN may be possible in clinical practice. On the contrary, to accurately diagnose biliopancreatic diseases other than IPMN, comprehensive diagnosis using multiple modalities may be necessary, rather than relying on CH-EUS alone.